



## PRESS RELEASE

# CARMAT receives the *Microns d'Or* Honorary Award

**Paris, September 23, 2014**

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, today announces that, at the Micronora international microtechnology trade fair in Besançon, Eastern France, it received the " *Microns d'Or* Honorary Award for the development and creation of a self-regulated bioprosthetic artificial heart with a proprietary micropump qualified by IREIS<sup>1</sup> and produced by the Pack'aéro Group<sup>1</sup>.

The *Microns d'Or* awards innovative microtechnological achievements presented for the first time within the framework of the Micronora trade fair. Consisting of manufacturers and researchers who are active in the field of microtechnology, the jury felt that the CARMAT bioprosthesis is an exceptional example of just what combining micromechanics, electronics, IT and sensors can achieve.

*Banque Populaire de Bourgogne-Franche-Comté*, official partner of the *Microns d'Or*, presented CARMAT with €1,000 to mark this achievement. The Company decided to donate this money to an engineering university, and thus gave it to Besançon's *École Nationale Supérieure de Mécanique et des Microtechniques* (ENSMM, the national engineering institute in mechanics and microtechnologies), a member of the POLYMECA network.

"*CARMAT encourages young engineers to become involved in the technological development of innovative projects*", says Marc Grimmé, CARMAT's Technical Director, adding "*Our self-regulating bioprosthesis is the result of a unique combination of technical and medical expertise. Micromechatronics has been a major component in its development. We are very honored to have received this award, which represents recognition, by professionals in this demanding specialty, of the innovative nature of our prosthesis and the quality of the French industrial network united by CARMAT around this project.*"

CARMAT, IREIS and the Pack'Aéro group, its partners within the framework of the French industrial strategic innovation Bpifrance contract, are attending the "Zoom Micromechatronics" part of the 2014 Micronora trade fair from September 23 to 26.

### **About CARMAT: the world's most advanced total artificial heart project**

**The only credible response for all cases of end-stage heart failure, which is a real public health issue:** CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

**The result of combining two types of unique expertise:** the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

**Imitating the natural heart:** given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

**A project leader acknowledged at a European level:** with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

**Strongly committed, prestigious founders and shareholders:** [Truffle Capital](#), a leading European venture capital firm, [Airbus Group](#), Professor [Alain Carpentier](#), the [Centre Chirurgical Marie Lannelongue](#) and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

---

<sup>1</sup> French companies part of CARMAT's industrial network since its inception – refer to next page for more details about these companies.

**For more information:** [www.carmatsa.com](http://www.carmatsa.com)

**About IREIS:**

IREIS, HEF group research center, is a contract research company specializing in surface engineering. IREIS studies surface properties, improves them by adding new features and develops industrial solutions. To achieve this, it focuses on 3 key areas of expertise: tribology, thin films and plasma sources, diffusion layers and ionic liquid.

**For further information:** [www.ireis.fr](http://www.ireis.fr)

**About Pack'aéro:**

The Pack'Aéro group has over 50 years of experience built around high-precision mechanics, and has over 200 members of staff. The group has three integrated and complementary skill divisions: *Pack'Aéro Mécatronique* (engineering / mechatronics), which offers complex systems, proprietary or co-designed, integrating mechanics, electrotechnics and electronics; *Vignal-Artru Industries* (the group's historical core business), which focuses on high-precision small mechanical parts; and *TMD*, which offers 'end-of-range' treatments including surface treatments, non-destructive testing and painting.

**For further information:** [www.packaero.com](http://www.packaero.com)

**About Micronora: International microtechnology and precision trade fair devoted to leading-edge technology**

This multi-technology professional trade fair focusing on microtechnology covers a broad range of domains, from R&D to subcontracting, and even production technology. Created 40 years ago, Micronora has expanded regularly and benefits from a strong reputation in France and abroad.

**For further information:** [www.micronora.com](http://www.micronora.com)

**About ENSMM: National engineering institute in mechanics and microtechnologies**

ENSMM is the only engineering university in France focusing primarily on microtechnologies. Students receive solid scientific and technological training in mechanical systems engineering and acousto-opto-electronic microsystems, supplemented by training in social and human sciences, languages, management and professional projects.

**For further information:** [www.ens2m.fr](http://www.ens2m.fr)

•••

**Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the *Document de Référence* filed with the *Autorité des Marchés Financiers* under number D.14-045 on March 17, 2014 and the *Note d'Opération* that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which Carmat operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark.

•••

**CARMAT**  
**Marcello Conviti**  
CEO

**Patrick Coulombier**  
COO

**Valérie Leroy**  
Director of Marketing  
& Investor Relations  
Tel.: +33 (0)1 39 45 64 50  
[contact@carmatsas.com](mailto:contact@carmatsas.com)

**Alize RP**  
Press Relations

**Caroline Carmagnol**  
Tel.: +33 (0)1 70 22 53 90  
[caroline@alizerp.com](mailto:caroline@alizerp.com)



**NewCap**  
Financial Communication  
and Investor Relations

**Dusan Oresansky**  
**Emmanuel Huynh**  
Tel.: +33 (0)1 44 71 94 94  
[carmat@newcap.fr](mailto:carmat@newcap.fr)

Name: **CARMAT**  
ISIN code: **FR0010907956**  
Ticker: **ALCAR**